FHIT蛋白在宫颈癌中的表达及临床意义

Expression of FHIT and Clinical Significance in Cervix Carcinoma

为探讨 FHIT的表达与宫颈癌临床病理指标及预后之间的关系 ,应用免疫组化方法检测 5 0例宫颈癌和 2 0例正常宫颈组织中 FHIT蛋白的表达。结果显示 ,5 0例宫颈癌中 ,2 7例显示 FHIT蛋白表达降低或缺失 ,FHIT表达的降低或缺失与肿瘤的组织学分级 (P=0 .0 0 2 )和淋巴结转移 (P=0 .0 16)明显相关 ;FHIT表达阳性者和阴性者的 3年生存率分别为 83 .3 %和 5 2 .2 % ,差异有显著性 (P=0 .0 3 7)。

The aim of this study was to investigate the expression of FHIT and their relationship with clinicopathologic parameters and prognosis in cervix carcinoma. Immunohistochemical analysis was performed in 50 invasive cervix carcinomas and 20 normal cervix tissues. Twenty seven tumors exhibited loss of FHIT expression. Loss of FHIT protein correlated significantly with histological grade( P =0.002) and lymph node metastasis( P =0.016). The 3-year survival for patients whose tumors displays positive FHIT expression versus negative FHIT expression was 83.3% versus 52.2%, respectively. There was statistical diffrence between them( P =0.037).